Abstract
The management of locally advanced breast cancer and, in some cases, operable node-positive disease, includes neoadjuvant chemotherapy (with or without HER2-targeted therapies), surgery, and locoregional radiotherapy. Pathological complete response to neoadjuvant therapy is considered an important prognostic factor in locally advanced breast cancer, but such prognostic information is primarily relevant in triple-negative breast cancer and HER2-positive subtypes.1,2 In luminal breast cancer, systemic chemotherapy can result in clinical downstaging or clinical response, but pathological complete response is not reached in most cases making the use of this endpoint of questionable value in this subtype.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
